DOCOMO to Exhibit at MWC Barcelona 2025, World's Largest Connectivity Exhibition
24.1.2025 06:01:00 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2025, the world's largest connectivity exhibition, in Barcelona, Spain from March 3 to 6. DOCOMO and its parent NTT Group will showcase technologies and initiatives focused on the core themes of non-terrestrial networks (NTN) and aerospace, open radio access networks (Open RAN), and entertainment, aiming to promote international standardization and new business focused on next-generation communication technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123714093/en/
NTT DOCOMO Booth at MWC Barcelona 2025 (Graphic: Business Wire)
DOCOMO is developing cutting-edge technologies and businesses under its brand slogan “Bridging Worlds for Wonder & Happiness.”
In the NTN and aerospace field, DOCOMO will highlight its latest initiatives under the NTT Group’s “NTT C89” space-business strategy, such as mobile-connectivity services using unmanned vehicles, or high-altitude platform stations (HAPS), that fly in the stratosphere for days or months, using relays to provide mobile connectivity in mountainous and remote areas, including at sea and in the sky.
For Open RAN, DOCOMO will showcase collaborations with global telecom operators, and also Open RAN services that leverage the strengths of various global partners, offered by OREX SAI, INC., a joint venture with NEC.
In the entertainment field, DOCOMO will display MiRZA® XR glasses by NTT QONOQ Devices, Inc., designed for diverse use cases including enterprise solutions, including a touch-and-try demonstration of the NTT XR Real Support solution for remote work enabled by XR glasses. A commercial prototype of AR glasses, which are scheduled to be released from this summer onwards, will also be on display (final specifications may vary).
Additionally, DOCOMO will showcase FEEL TECH®,an innovative technology that transforms how sensory information are shared, tailoring to the other person’s unique perception. Through a demonstration that conveys the emotions and sensations of characters alongside visuals and sound, visitors will have the opportunity to experience DOCOMO’s vision for the future of entertainment.
DOCOMO will also showcase the Virtual EXPO of Expo 2025 primarily developed by NTT QONOQ, INC. aiming for a service launch in April. This virtual site allows visitors to experience the NTT Pavilion using various devices.
DOCOMO’s booth at MWC Barcelona 2025 will be located at Stand 4E50 in Hall 4. During the exhibition, Mr. Sadayuki Abeta, Chief Open RAN Strategist at NTT DOCOMO and Chief Technology Officer at OREX SAI, will give a presentation on his company’s latest initiatives, case histories and future plans at the MWC Broadcast Stage 2025 in Hall 4 on Tuesday, March 4 from 16:15 to 16:45 (please see MWC Barcelona 2025 website to confirm final content and schedule).
About MWC Barcelona 2025
https://www.mwcbarcelona.com/
When:
March 3 to 6
08:30 to 19:00 (16:00 on last day)
Where:
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
NTT C89 is pending trademark registration.
MiRZA® is a registered trademark of NTT QONOQ Devices, Inc. in Japan.
FEEL TECH® is a registered trademark of NTT DOCOMO, INC. in Japan
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 89 million subscribers, is one of the global leaders in 3G, 4G and 5G mobile network technologies.
Under the slogan "Bridging Worlds for Wonder & Happiness," DOCOMO is actively collaborating with global partners to expand its business scope from mobile services to comprehensive solutions, aiming to deliver unsurpassed value and drive innovation in technology and communications, ultimately to support positive change and advancement in global society.
https://www.docomo.ne.jp/english/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123714093/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom